Overview

A Phase 2 Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

Status:
NOT_YET_RECRUITING
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This Study is a Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus.
Phase:
PHASE2
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited